Observation on the Therapeutic Effect of Hypotonic Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Advanced Gastric Cancer and Ovarian Cancer Accompanied by Ascites

Objective: To observe the time of ascites disappearance, time to ascites recurrence, improvement rate in quality of life, and the effective rate of ascites treatment in patients with advanced gastric and ovarian cancer with ascites following hypotonic hyperthermic intraperitoneal chemotherapy. Methods: Forty patients with advanced gastric and ovarian cancer with ascites, treated in our hospital from January 2021 to August 2024, were selected as research subjects. They were divided into a treatment group and a reference group using a random number table method. The treatment group received hypotonic hyperthermic intraperitoneal chemotherapy, while the reference group received conventional treatment. The treatment effects of the two groups were compared. Results: In the treatment group, the ascite disappearance time was (6.13 ± 1.32) days, and the recurrence time was (22.58 ± 8.21) months. The ascite disappearance time was significantly shorter than that of the reference group, and the ascite recurrence time was significantly longer. Both P-values were less than 0.05, indicating statistical significance. The effective rate of quality of life improvement was 95%, with only 1 patient showing a decrease in quality of life. The effective rate of ascites treatment was 95%, with only 1 patient showing an increase in ascites. Both the quality of life improvement rate and the effective rate of ascites treatment were significantly higher than those of the reference group, with P-values of 0.037 and 0.018, respectively, indicating statistical significance. Conclusion: For patients with advanced gastric and ovarian cancer with ascites, hypotonic hyperthermic intraperitoneal chemotherapy can accelerate ascites disappearance, prolong the time to recurrence, and significantly improve both the quality of life improvement rate and the effective rate of ascites treatment.